T1	duration 0 12	Fifteen-year
T2	intervention 56 67	fenretinide
T3	No-of-participants 494 498	1739
T4	average-age 505 515	aged 30-70
T5	intervention-participants 517 520	872
T6	control-participants 548 551	867
T7	control 559 570	observation
T8	outcome-Measure 662 690	second primary breast cancer
T9	outcome 727 758	number of second breast cancers
T10	intervention-value 763 766	168
T11	control-value 794 797	190
T12	intervention-value 870 872	83
T13	control-value 907 910	126
T16	intervention-value 993 995	85
T17	control-value 1000 1002	64
T19	outcome 1292 1361	difference in cancers in other organs, distant metastases or survival
T14	outcome 934 956	in premenopausal women
T15	outcome 1010 1033	in postmenopausal women
